Results 81 to 90 of about 28,869 (265)

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1195-1204, May 2026.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible? [PDF]

, 2016
The international community has committed to ending the epidemics of HIV/AIDS, tuberculosis, malaria, and neglected tropical infections by 2030, and this bold stance deserves universal support.
Harries, Anthony D, Kyaw, Nang Thu Thu, Suthar, Amitabh B, Takarinda, Kudakwashe C, Tayler-Smith, Katie, Tweya, Hannock, Zachariah, Rony   +6 more
core   +2 more sources

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV

HIV Research & Clinical Practice
Background Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; however, there is little data describing its ...
Arianna E Kousari, Melissa P. Wilson, Kellie L. Hawkins, M. Bandali, A. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson   +6 more
semanticscholar   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

The changing face of an epidemic: healthy old age with HIV [PDF]

, 2017
The demographics of the HIV epidemic in the UK have changed significantly. Owing to a steady rate of new diagnoses and improved survival, the population of individuals living with HIV continues to increase.
Chowdhury, M, Nugent, DB, Waters, LJ
core   +1 more source

Tenofovir Alafenamide [PDF]

Reactions Weekly, 2020
  +4 more sources

Evaluation of Relative Bioavailability and Food Effect of a Fixed‐Dose Combination Tablet of Islatravir and Lenacapavir

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Long‐acting oral HIV‐1 treatments can potentially reduce pill burden, treatment fatigue, suboptimal adherence, and treatment failure. A combination of islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a capsid inhibitor, is being investigated as a weekly oral HIV‐1 treatment.
Jing Niu, Haeyoung Zhang, John Ling, Sharline Madera, Nerissa Kwok, Steve West, Diane Longo, Gillian Gillespie, Cyril Llamoso, Dhananjay D. Marathe   +9 more
wiley   +1 more source

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng   +12 more
wiley   +1 more source

Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV

Clinical Infectious Diseases
Background Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF ...
J. Damas, Aline Munting, J. Fellay, D. Haerry, C. Marzolini, Philip E Tarr, Ana Steffen, Dominique L Braun, M. Stoeckle, E. Bernasconi, Olivier Nawej Tshikung, C. Fux, K. Darling, C. Béguelin, G. Wandeler, M. Cavassini, B. Surial   +16 more
semanticscholar   +1 more source